COVID-19-associated liver injury: from bedside to bench
D Li, X Ding, M Xie, D Tian, L Xia - Journal of Gastroenterology, 2021 - Springer
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has been a global challenge since December …
syndrome coronavirus 2 (SARS-CoV-2), has been a global challenge since December …
Macrophage activation syndrome and COVID-19
R Otsuka, K Seino - Inflammation and regeneration, 2020 - Springer
An emerging, rapidly spreading coronavirus SARS-CoV-2 is causing a devastating
pandemic. As we have not developed curative medicine and effective vaccine, the end of …
pandemic. As we have not developed curative medicine and effective vaccine, the end of …
Immune-and non-immune-mediated adverse effects of monoclonal antibody therapy: a survey of 110 approved antibodies
BA Baldo - Antibodies, 2022 - mdpi.com
Identification of new disease-associated biomarkers; specific targeting of such markers by
monoclonal antibodies (mAbs); and application of advances in recombinant technology …
monoclonal antibodies (mAbs); and application of advances in recombinant technology …
Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors
AL Gavin, D Huang, TR Blane, TC Thinnes… - Nature …, 2021 - nature.com
Abstract Phospholipase D3 (PLD3) and PLD4 polymorphisms have been associated with
several important inflammatory diseases. Here, we show that PLD3 and PLD4 digest ssRNA …
several important inflammatory diseases. Here, we show that PLD3 and PLD4 digest ssRNA …
COVID-19: infection or autoimmunity
T Icenogle - Frontiers in immunology, 2020 - frontiersin.org
The clinical and laboratory features of COVID-19 are reviewed with attention to the
immunologic manifestations of the disease. Recent COVID-19 publications describe a …
immunologic manifestations of the disease. Recent COVID-19 publications describe a …
COVID-19 cytokine storm: targeting the appropriate cytokine
RQ Cron - The Lancet Rheumatology, 2021 - thelancet.com
As of January, 2021, nearly 2-million deaths worldwide have been attributed to COVID-19,
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Much …
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Much …
A rationale for targeting the P2X7 receptor in Coronavirus disease 19
F Di Virgilio, Y Tang, AC Sarti… - British Journal of …, 2020 - Wiley Online Library
Severe pneumonia which shares several of the features of acute respiratory distress
syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 …
syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 …
SARS‐CoV‐2‐mediated immune system activation and potential application in immunotherapy
Y Tan, F Tang - Medicinal research reviews, 2021 - Wiley Online Library
Although novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐mediated
pulmonary inflammation has recently attracted great attention, its pathology and …
pulmonary inflammation has recently attracted great attention, its pathology and …
Early phases of COVID-19 are characterized by a reduction in lymphocyte populations and the presence of atypical monocytes
A Lombardi, E Trombetta, A Cattaneo… - Frontiers in …, 2020 - frontiersin.org
Background Severe acute respiratory syndrome coronavirus 2 is a recently discovered
pathogen responsible of coronavirus disease 2019 (COVID-19). The immunological …
pathogen responsible of coronavirus disease 2019 (COVID-19). The immunological …
[HTML][HTML] Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg
C Crayne, RQ Cron - European journal of rheumatology, 2020 - ncbi.nlm.nih.gov
Macrophage activation syndrome (MAS) is the name given to secondary hemophagocytic
lymphohistiocytosis (sHLH) associated with rheumatic diseases. Previously, MAS has been …
lymphohistiocytosis (sHLH) associated with rheumatic diseases. Previously, MAS has been …